CSIMarket Company Name, Ticker, Industry, else..
 
Cel sci Corporation  (NYSE: CVM)
Other Ticker:  
 
 
Price: $0.2038 $-0.02 -8.610%
Day's High: $0.2319 Week Perf: -21.28 %
Day's Low: $ 0.20 30 Day Perf: -14.76 %
Volume (M): 4,065 52 Wk High: $ 2.22
Volume (M$): $ 828 52 Wk Avg: $0.76
Open: $0.23 52 Wk Low: $0.18



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 85
 Employees 30
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Cel Sci Corporation
Cel-Sci Corporation is a biotechnology company that focuses on the development of immunotherapy treatments for cancer and other diseases. The company's lead product, Multikine, is a potential immunotherapy treatment for head and neck cancer that is currently in late-stage clinical trials. Cel-Sci also has a platform technology called L.E.A.P.S. (Ligand Epitope Antigen Presentation System) that allows for the development of targeted immunotherapies for a variety of diseases. The company is headquartered in Vienna, Virginia, and is traded on the NYSE American exchange under the ticker symbol CVM.


   Company Address: 8229 Boone Boulevard Vienna 22182 VA
   Company Phone Number: 506-9460   Stock Exchange / Ticker: NYSE CVM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        5.16% 
CRDF        6.99% 
EXEL        20.95% 
GILD        10.05% 
IKNA   -4.31%    
IOVA        2.23% 
• View Complete Report
   



Cel Sci Corporation

Cel Sci Corporation Sees Improvement in Operating Shortfall in Q2 2024

In the Biotechnology & Pharmaceuticals sector, contributors are examining the second quarter performance of companies, particularly focusing on Cel Sci Corporation. The company has reported an operating shortfall of $-7.075948 million for the period of January to March 31, 2024. However, it is important to note that the company has not provided any details regarding its top-line performance yet during this reporting season.
Comparing the current quarter to the same period last year, it is evident that Cel Sci Corporation has improved its efficiency in conducting business. In the previous year, the company experienced an operating shortfall of $-8.176246 million. However, in the fiscal second quarter of 2024, the company managed to operate more effectively, reducing the losses to $-7.245 million.
Cel Sci Corporation

Cel Sci Corporation's Revolutionary Discovery Shakes Stock Market Amidst First Quarter Losses in 2024



Investors are always on the lookout for potential growth opportunities and developments in the stock market. A recent earnings cycle from October to December 2023 has shed light on some interesting facts about a company's financial performance. While stockholders had not anticipated any major changes, the company managed to operate more cost-effectively, significantly reducing its operating loss and improving its overall deficit.
Evolving Business demonstrates increased efficiency:
One of the key highlights of this earnings cycle is the company's ability to operate much more efficiently compared to the previous year. In the same period, the company recorded an operating loss of $-6.485887 million, a significant improvement from the previous year's figure of $-7.650549 million. This data showcases the evolving business's capacity to manage costs and optimize operations, leading to a reduction in losses.
Cel Sci Corporation

Cel Sci Corporation's Financials Raise Concerns as Expenses Surge in Fiscal Fourth Quarter of 2023



The Biotechnology & Pharmaceuticals industry has been closely observed during the July to September reporting cycle, with many companies disclosing their financial results. One such company is Cel Sci Corporation, which recently reported an operating shortfall of $-7.467522 million for the financial period ending Sep 30, 2023. Although the results may seem discouraging at first glance, a comprehensive analysis reveals a more bullish outlook for the company.
Operating Surplus Comparison:
Comparing the operating surplus of the fourth quarter of 2022 with the same period in 2023, the difference is striking. In 2022, Cel Sci Corporation achieved a commendable operating surplus of $18.290441 million. However, in the fiscal fourth quarter of 2023, the company faced challenges and reported a net loss of $-7.631 million in contrast.
Cel Sci Corporation

Cel Sci Corporation Shows Promising Improvement in Financial Performance, Drastically Reducing Operating Losses in Q3 2023

Following the earnings reports of various businesses in the Biotechnology & Pharmaceuticals industry, some lesser-known companies are starting to gain attention. One such company is Cel Sci Corporation (CVM), which recently revealed a significant improvement in its operating loss for the third quarter of 2023. The company reported a loss of $-8.181757 million, compared to a loss of $-27.114625 million in the same three-month period the previous year.
This improvement in operating loss suggests that Cel Sci Corporation has become more cost-effective in its operations, which is an encouraging sign for investors. The company has managed to reduce its losses to $-8.367 million during the third quarter of 2023. This positive outcome indicates that Cel Sci Corporation is making strides towards financial stability and profitability.
Cel Sci Corporation

Cel Sci Corporation's Operating Deficit Improves to $-18.4 Million in Q2 2023, Indicating Potential Growth Amidst Biotech & Pharma Industry

Investing in the stock market can be a daunting endeavor, but keeping an eye on industry leaders can help guide you in making well-informed decisions. One such company to consider is Cel Sci Corporation, an esteemed Biotechnology & Pharmaceuticals enterprise. While they have recorded a cumulative net loss of $-27 million during the 12 months ending in the second quarter of 2023, analysts predict future growth for this corporation.
Despite experiencing a negative return on equity (ROE) of -90.48%, it is essential to note that 110 other companies within the Biotechnology & Pharmaceuticals industry recorded a higher ROE. In the total ranking, Cel Sci Corporation's ROE has dropped compared to the first quarter of 2023 from 0 to 2511, which is not ideal, but it is not altogether detrimental either. Biotechnology & Pharmaceuticals industry experts continue to scrutinize the second quarter of 2023, but the present operating deficit of $-8.176246 million gives cause for optimism.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com